Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B

Silva, Luiz Caetano da; Nova, Maria Luiza da; Ono‐Nita, Suzane Kioko; Pinho, João Renato Rebello; Sitnik, Roberta; Santos, Vera Aparecida dos; Carrilho, Flair José

doi:10.1590/s0036-46652009000500005

Cited by 12 publications

(8 citation statements)

References 36 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study of da Silva et al. [38] has provided some evidence that slow responders, characterized by a decrease in serum HBV DNA accompanied by a slow, but stepwise decrease in HBeAg, could also obtain a favourable outcome (HBeAg seroconversion) by a prolongation of peginterferon alfa‐2a plus lamivudine treatment. In the current study, 16 of 47 patients who did not develop CVR after 96 weeks of entecavir therapy showed a slow virological response pattern.…”

Section: Discussionmentioning

confidence: 99%

An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg‐positive patients

Zhang

et al. 2011

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Quantification of HBeAg levels has been found to be useful in monitoring and predicting the outcomes of interferon and lamivudine treatment in HBeAg-positive patients. The aim of this study was to determine whether quantification of HBeAg at baseline and on treatment could predict which patients would achieve HBeAg seroconversion after 96 weeks of entecavir therapy. Sixty-five HBeAg-positive naïve chronic hepatitis B patients who were treated with entecavir at a dose of 0.5 mg once daily for 96 weeks were evaluated. Serum HBV DNA levels were assessed at baseline, week 24, 48 and 96; serum HBeAg levels were assessed at baseline, week 12, 24, 48, 72 and 96. Serum HBeAg levels were associated with a higher likelihood of HBeAg seroconversion to entecavir at weeks 96 than serum HBV DNA levels both at baseline and on treatment (at baseline: OR = 9.932, P = 0.003 vs. OR = 5.045, P = 0.036; on treatment: OR = 112.5, P < 0.0001 vs. OR = 47.782, P < 0.0001). A maintained reduction in HBeAg > 65% of pretreatment HBeAg values after 24 weeks of entecavir therapy is the strongest predictor for HBeAg seroconversion at week 96 (OR = 70.578, P < 0.0001). Quantification of HBeAg at the start and early during therapy showed a higher predictive value than that of HBV DNA for HBeAg seroconversion by entecavir. A significant decrease in serum HBeAg levels at week 24 may be a useful on-treatment measurement in the early phase for predicting HBeAg seroconversion and identifying patients who will most likely benefit from finite entecavir treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg‐positive patients

Zhang

et al. 2011

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“… 17 All HBV genotypes found in Brazilian patients and described in previous studies were detected with the same primers used in this study. 17 , 21 The primers selected for HCV target the conserved 5′ non-translated region of the viral RNA. According to the literature, all genotypes of HCV can be detected with these primers.…”

Section: Discussionmentioning

confidence: 99%

In-house quantitative real-time PCR for the diagnosis of hepatitis B virus and hepatitis C virus infections

Zauli¹,

Menezes

Oliveira³

et al. 2016

Brazilian Journal of Microbiology

View full text Add to dashboard Cite

The quantification of viral nucleic acids in serum by real-time PCR plays an important role in diagnosing hepatitis B virus and hepatitis C virus infection. In this study, we developed an assay using specific primers and probes to quantify hepatitis B virus DNA or hepatitis C virus RNA in serum from infected patients. For standardization and validation of the assay, an international panel of hepatitis B virus/hepatitis C virus and standard plasmids was used. A correlation coefficient of 0.983 and 0.963 for hepatitis B virus and hepatitis C virus, respectively, was obtained based on cycle threshold values and concentrations of DNA or RNA. The standard curve showed a linear relationship from 19 IU/mL to 1.9 × 109 IU/mL of serum, with a coefficient of determination (r2) of 0.99. In sera from patients infected with hepatitis B virus or hepatitis C virus viral loads (19 IU/mL and 1.9 × 109 IU/mL), we quantified viral loads with a detection limit of 1.9 × 102 IU/mL. The real-time quantitative PCR assay developed in this study provides an ideal system for routine diagnosis and confirmation of indeterminate serological results, especially in immunosuppressed patients.

show abstract

“…HBV infection is a disease that leads to immune‐mediated damage [Dunn et al, ; Chisari et al, ; Das and Maini, ; McMahon, ; Stauffer et al, ; Busca and Kumar, ]. HBsAg and HBeAg are important indicators that reflect the degree of proliferation of the virus [Da Silva et al, ; Nguyen et al, ]. TMHB‐Ag‐positive implies higher levels of HBsAg and HBeAg than of antibodies, making TMHB‐Ag indicators of exacerbation of HBV infection.…”

Section: Discussionmentioning

confidence: 99%

Establishment of a simple model for hepatitis B virus infection status based on trait marker from quantitative measurement of serum markers

Zhang

Liu

2015

Journal of Medical Virology

View full text Add to dashboard Cite

The objectives of this study were to establish a simple model based on quantitative serum markers of hepatitis B virus (HBV) infection to understand the complex immune response to HBV. Patients samples were obtained from individuals with active HBV infection (alanine transaminase [ALT]-positive, aspartate aminotransferase [AST]-positive and HBsAg-positive), or patients who had recovered from infection (ALT-negative, AST-negative, anti-HBs-positive and either HBsAg, HBeAg, anti-HBe or anti-HBc positive). HBV quantitative markers, including HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc, were measured using a chemiluminescent microparticle immunoassay. Based on cut-off values, anti-HBs levels were converted to a ratio (sample value/cut-off value, RV). Anti-HBe and anti-HBc levels were determined using a competition method, resulting in the use of a ratio (cut-off value/sample value, RV) for determination of anti-HBe and anti-HBc values. The greater RV value in a patient was considered as a trait marker for HBV infection (TMHB) of this patient. Patients with TMHB including HBsAg or HBeAg were defined as TMHB-Ag; and patients with TMHB including anti-HBs, anti-HBe, or anti-HBc TMHB were defined as TMHB-Ab. The percentage of patients determined to be TMHB-Ag was 96.3% in the HBV group. The percentage of patients determined to be TMHB-Ab was 94.7% in recovery group. TMHBs could be used to analyze different status of HBV infection.

show abstract

Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B

Cited by 12 publications

References 36 publications

An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg‐positive patients

An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg‐positive patients

In-house quantitative real-time PCR for the diagnosis of hepatitis B virus and hepatitis C virus infections

Establishment of a simple model for hepatitis B virus infection status based on trait marker from quantitative measurement of serum markers

Contact Info

Product

Resources

About